Bioconjugation strategies and clinical implications of Interferon-bioconjugates.

Interferons (IFN) are immunomodulating, antiviral and antiproliferative cytokines for treatment of multiple indications, including cancer, hepatitis, and autoimmune disease. The first IFNs were discovered in 1957, first approved in 1986, and are nowadays listed in the WHO model list of essential medicines. Three classes of IFNs are known; IFN-α2a and IFN-β belonging to type-I IFNs, IFN-γ a type-II IFN approved for some hereditary diseases and IFN-λs, which form the newest class of type-III IFNs. IFN-λs were discovered in the last decade with fascinating yet under discovered pharmaceutical potential. This article reviews available IFN drugs, their field and route of application, while also outlining available and future strategies for bioconjugation to further optimize pharmaceutical and clinical performances of all three available IFN classes. Copyright © 2022 Elsevier B.V. All rights reserved.

Citation

Niklas Hauptstein, Lorenz Meinel, Tessa Lühmann. Bioconjugation strategies and clinical implications of Interferon-bioconjugates. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2022 Mar;172:157-167

Mesh Tags

Substances

PMID: 35149191

search → result